Amgen Inc (AMGN)vsNewmont Goldcorp Corp (NEM)
AMGN
Amgen Inc
$331.70
+0.79%
HEALTHCARE · Cap: $177.71B
NEM
Newmont Goldcorp Corp
$116.51
+2.66%
BASIC MATERIALS · Cap: $124.38B
Smart Verdict
WallStSmart Research — data-driven comparison
Amgen Inc generates 49% more annual revenue ($37.22B vs $24.97B). NEM leads profitability with a 33.9% profit margin vs 21.0%. AMGN appears more attractively valued with a PEG of 2.18. NEM earns a higher WallStSmart Score of 78/100 (B+).
AMGN
Buy62
out of 100
Grade: C+
NEM
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.2%
Fair Value
$321.89
Current Price
$331.70
$9.81 premium
Margin of Safety
-81.0%
Fair Value
$68.86
Current Price
$116.51
$47.65 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 101 in profit
Strong operational efficiency at 33.8%
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Generating 1.5B in free cash flow
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 61.4%
Revenue surging 45.8% year-over-year
Earnings expanding 78.6% YoY
Conservative balance sheet, low leverage
Large-cap with strong market position
Areas to Watch
Expensive relative to growth rate
Trading at 19.5x book value
4.4% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.0% and operating margin at 33.8%.
Bull Case : NEM
The strongest argument for NEM centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 33.9% and operating margin at 61.4%. Revenue growth of 45.8% demonstrates continued momentum.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, Price/Book, EPS Growth.
Bear Case : NEM
The primary concerns for NEM are PEG Ratio.
Key Dynamics to Monitor
AMGN profiles as a mature stock while NEM is a growth play — different risk/reward profiles.
NEM carries more volatility with a beta of 0.45 — expect wider price swings.
NEM is growing revenue faster at 45.8% — sustainability is the question.
NEM generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
NEM scores higher overall (78/100 vs 62/100), backed by strong 33.9% margins and 45.8% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →Newmont Goldcorp Corp
BASIC MATERIALS · GOLD · USA
Newmont Corporation, based in Greenwood Village, Colorado, United States, is one of the largest gold mining companies in the world.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?